JOURNAVX met the primary endpoint by demonstrating statistically significant superior reduction in pain vs placebo. 1,b JOURNAVX did not meet the first key secondary endpoint that hypothesized ...

Prof. Dr. Guido van Wingen discusses the potential of, and barriers to, the use of AI in transforming the treatment of depression ...

Researchers from the Johns Hopkins Kimmel Cancer Center and The Johns Hopkins University have created a novel database structure that allows investigators anywhere to more easily study multiple types ...

Researchers from the Johns Hopkins Kimmel Cancer Center and The Johns Hopkins University have created a novel database structure that allows investigators anywhere to more easily study multiple types ...

The partnership connects structured clinical data with EHR workflows to accelerate referrals, care coordination, and ...

Povorcitinib 75 mg achieved high-threshold lesion clearance by week 12, including 100% draining-tunnel reduction in 12%–57% and total abscess clearance in 22%–62% of participants. Phase 3 data show ...

This study represents a proof-of-principle retrospective cohort analysis and review of select radiation treatment data from the VA Radiation Oncology Quality Surveillance Program (VAROQS) initiative.

Zygomatic implants represent one of the most significant advances in treatment options for seniors with severe maxillary bone ...

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics ...

When Jon and Dayla Culp received the news that their six-year-old Labrador retriever, Clarice, had a malignant tumor near her left wrist, the couple was devastated. Dayla had lost her sister, Darcy ...